Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutid...

Eligibility Criteria

Inclusion

  • Type 2 diabetic
  • Treated with OHA (oral hypoglycaemic agent monotherapy for at least 3 months. Prior use of metformin is allowed
  • Body Mass Index (BMI) between 27.0-42.0 kg/m\^2 (inclusive)
  • HbA1c maximum 10% based on analysis from central laboratory

Exclusion

  • Cardiac problems
  • Uncontrolled treated/untreated hypertension
  • Proliferative retinopathy or known autonomic neuropathy
  • Recurrent severe hypoglycemia as judged by the investigator
  • Known or suspected allergy to trial product or related products
  • Use of any drug (except for OHAs), which in the investigators opinion could interfere with the glucose level or body weight or any contraindication to metformin use or intolerance to metformin 1000 mg (prior to trial entry or during run-in period). Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
  • Known or suspected abuse of alcohol or narcotics
  • Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
  • TSH (thyroid stimulating hormone) below 0.2 or above 15 U/mL
  • Type 1 or other specific causes of diabetes

Key Trial Info

Start Date :

February 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2001

Estimated Enrollment :

223 Patients enrolled

Trial Details

Trial ID

NCT01511198

Start Date

February 1 2001

End Date

October 1 2001

Last Update

January 26 2017

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

Novo Nordisk Investigational Site

Vestavia Hills, Alabama, United States, 35209

2

Novo Nordisk Investigational Site

Tucson, Arizona, United States, 85719

3

Novo Nordisk Investigational Site

Carlisle, Arkansas, United States, 72024

4

Novo Nordisk Investigational Site

Jonesboro, Arkansas, United States, 72401